Related Experiment Video
Updated: Aug 13, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Clinical potential of GABAB receptor modulators
1Department of Anaesthesia and Intensive Care, The University of Adelaide, Australia. jennifer.ong@adelaide.edu.au
New phenylalkylamines act as positive allosteric modulators of GABAB receptors, offering a selective approach to drug discovery for neurological disorders without agonist side effects.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Metabotropic gamma-aminobutyric acid (B) (GABAB) receptors are G-protein-coupled receptors (GPCRs) crucial for inhibiting neurotransmission and controlling neuronal excitability.
- Dysfunction of GABAB receptors is linked to various neurological and psychiatric conditions, including epilepsy, pain, depression, and addiction.
- GABAB receptors function as heterodimers of GABAB1 and GABAB2 subunits, with distinct roles in ligand binding and G-protein coupling.
Purpose of the Study:
- To introduce a novel class of phenylalkylamines as positive allosteric modulators (PAMs) for GABAB receptors.
- To explore the therapeutic potential of these PAMs in selectively enhancing GABAB receptor function.
- To highlight allosteric modulation as a strategy for developing drugs with reduced side effects compared to traditional agonists.
Main Methods:
- Review of existing literature on GABAB receptor structure, function, and pharmacology.
- Introduction of fendiline-based phenylalkylamines as lead compounds.
- Discussion of allosteric modulation principles and their application to GPCRs.
Main Results:
- Identification of a new class of phenylalkylamines that act as potent positive potentiators of GABAB receptor-mediated function.
- Demonstration that these modulators interact with allosteric sites, distinct from the conserved agonist binding region.
- Proposal that these allosteric modulators offer a selective means to target GABAB receptor pharmacology.
Conclusions:
- Positive allosteric modulators represent a promising therapeutic strategy for GABAB receptor-related disorders.
- Phenylalkylamine-based PAMs provide a novel avenue for drug discovery with potentially fewer side effects than GABAB agonists.
- Allosteric modulation of GABAB receptors offers an attractive approach to selectively modify receptor function and advance drug development.
More Related Videos
07:51Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
Published on: November 14, 2014
08:21Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
G-protein Coupled Receptors
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical, 7TM, or...